MXPA04000068A - Conjugados de progenipoyetina modificados quimicamente. - Google Patents

Conjugados de progenipoyetina modificados quimicamente.

Info

Publication number
MXPA04000068A
MXPA04000068A MXPA04000068A MXPA04000068A MXPA04000068A MX PA04000068 A MXPA04000068 A MX PA04000068A MX PA04000068 A MXPA04000068 A MX PA04000068A MX PA04000068 A MXPA04000068 A MX PA04000068A MX PA04000068 A MXPA04000068 A MX PA04000068A
Authority
MX
Mexico
Prior art keywords
modified
chemically
progenipoietin
conjugates
present
Prior art date
Application number
MXPA04000068A
Other languages
English (en)
Spanish (es)
Inventor
R Siegel Ned
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MXPA04000068A publication Critical patent/MXPA04000068A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MXPA04000068A 2001-06-22 2002-06-14 Conjugados de progenipoyetina modificados quimicamente. MXPA04000068A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30036201P 2001-06-22 2001-06-22
PCT/US2002/018810 WO2003000179A2 (en) 2001-06-22 2002-06-14 Chemically-modified progenipoietin conjugates

Publications (1)

Publication Number Publication Date
MXPA04000068A true MXPA04000068A (es) 2005-06-06

Family

ID=23158770

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000068A MXPA04000068A (es) 2001-06-22 2002-06-14 Conjugados de progenipoyetina modificados quimicamente.

Country Status (15)

Country Link
US (1) US20060052291A1 (https=)
EP (1) EP1404354A4 (https=)
JP (1) JP2005512951A (https=)
KR (1) KR20040069980A (https=)
CN (1) CN101426511A (https=)
BR (1) BR0211192A (https=)
CA (1) CA2450950A1 (https=)
CZ (1) CZ20033537A3 (https=)
EA (1) EA006368B1 (https=)
IL (1) IL159496A0 (https=)
MX (1) MXPA04000068A (https=)
NO (1) NO20035742L (https=)
PL (1) PL367410A1 (https=)
WO (1) WO2003000179A2 (https=)
ZA (1) ZA200309863B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2594666A1 (en) * 2005-02-16 2006-08-24 Micromet Ag Use of activated polymers for separation of protein and polypeptide multimers
US20060233740A1 (en) * 2005-03-23 2006-10-19 Bossard Mary J Conjugates of an hGH moiety and a polymer
EP2421881B1 (en) 2009-04-20 2016-04-13 The Regents of The University of California Engineered demeter 5-methylcytosine dna glycosylase with improved yield, stability and solubility
KR200483859Y1 (ko) 2015-10-28 2017-07-04 주식회사 키유틸리티 충전장치 수납 및 휴대용 기기 거치용 장치
AU2018348138A1 (en) * 2017-10-11 2020-04-23 Ambrx, Inc. Porcine G-CSF variants and their uses
WO2019129876A1 (en) * 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Process for providing pegylated protein composition
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU688321B2 (en) * 1993-04-21 1998-03-12 Institut Pasteur Biocompatible implant for the expression and secretion in vivo of a therapeutic compound
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
GB2294047A (en) * 1994-10-14 1996-04-17 Merck & Co Inc Synthetic peptides for use as epitopes specific for HIV
SE507527C2 (sv) * 1996-10-11 1998-06-15 Ericsson Telefon Ab L M Flerbandsmottagare som genererar en mellanfrekvens som är gemensam för de olika frekvensbanden, och förfarande för densamma
US6251665B1 (en) * 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom

Also Published As

Publication number Publication date
EA200400070A1 (ru) 2004-06-24
WO2003000179A2 (en) 2003-01-03
KR20040069980A (ko) 2004-08-06
JP2005512951A (ja) 2005-05-12
CN101426511A (zh) 2009-05-06
NO20035742L (no) 2004-02-23
ZA200309863B (https=) 2006-06-28
IL159496A0 (en) 2004-06-01
PL367410A1 (en) 2005-02-21
EP1404354A4 (en) 2005-04-20
EP1404354A2 (en) 2004-04-07
BR0211192A (pt) 2004-10-26
CA2450950A1 (en) 2003-01-03
WO2003000179A3 (en) 2003-12-11
CZ20033537A3 (cs) 2004-08-18
EA006368B1 (ru) 2005-12-29
NO20035742D0 (no) 2003-12-19
US20060052291A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
MXPA04004809A (es) Conjugados de hormona de crecimiento humana modificada quimicamente.
MXPA05004993A (es) Conjugados de hormona del crecimiento humana modificados quimicamente.
DE59905247D1 (de) Wässrige reaktive spachtelmassen (ii)
BR0212522A (pt) Ligando de ligação de zinco, hexâmero de insulina, preparação aquosa de insulina e métodos de prolongar a ação de uma preparação de insulina e de preparar um ligando de ligação de zinco
DE50202328D1 (de) Amidofunktionelle aminopolydiorganosiloxane
EA200900643A1 (ru) Пептиды, содержащие триптофан
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
WO2001076640A3 (en) Chemically modified novel erythropoietin stimulating protein compositions and methods
WO2003000038A3 (en) Compositions and methods for modulating plant development
TW200718237A (en) Link assignment messages in lieu of assignment acknowledgement messages
AU2003303598A1 (en) Compositions, methods, and systems for inferring bovine breed
BG108499A (en) A novel engineered superantigen for human therapy
ATE347057T1 (de) Federelement
DE60120712D1 (en) Kallikrein gen
MY122877A (en) Composition.
EP1412388A4 (en) HUMANIZED ANTIBODIES DERIVED FROM DD-3B6 / 22, SPECIFIC OF THE FIBRIN D-DIMER FRAGMENT
MXPA04000068A (es) Conjugados de progenipoyetina modificados quimicamente.
AU2001235783A1 (en) Therapeutic compositions for pulmonary delivery
WO2001076639A3 (en) Chemically-modified myelopoietin conjugates
MY147790A (en) Stable emulsion composition
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
ATE388723T1 (de) Zusammensetzung enthaltend epigallocatechin- gallat
TNSN07139A1 (en) 4-hydroxy tamoxifen gel formulations
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
IL152232A0 (en) Promoter to il-18bp, its preparation and use